Romidepsin
Nonmalignant Neoplasm
Asan Medical CenterSmall moleculePhase 2/3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Nonmalignant Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Thiotepa Roswell Park Cancer Institute | Phase 2/3 | B |
ETOPOSIDE Roswell Park Cancer Institute | Phase 2/3 | B |
Evomela Roswell Park Cancer Institute | Phase 2/3 | B |
Cyclophosphamide Roswell Park Cancer Institute | Phase 2/3 | B |
Carboplatin Roswell Park Cancer Institute | Phase 2/3 | B |
View all 19 →
Same molecule, other indications
Romidepsin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →